7

1 Biotech With Room to Run

This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

In this edition, David takes a closer lok at Affymax, which just saw approval for Omontys, its anemia drug for patients on dialysis. Can Omontys steal significant share of this multibillion-dollar market with its aggressive pricing scheme despite the heavyweights in the industry? Keep watching, and find out about another company poised to profit from Omontys' success.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Sending report...

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid